TIAA FSB’s NovoCure NVCR Stock Holding History

TIAA FSB’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,935	Closed	-$215K	–	587
2022 Q4	$215K	Hold	2,935	–	–	﹤0.01%	530
2022 Q3	$223K	Sell	2,935 -11	-0.4%	-$858	﹤0.01%	520
2022 Q2	$205K	Buy	+2,946	New	+$222K	﹤0.01%	566
2021 Q3	–	Sell	-13,741	Closed	-$3.05M	–	389
2021 Q2	$3.05M	Hold	13,741	–	–	0.01%	224
2021 Q1	$1.82M	Hold	13,741	–	–	0.01%	259
2020 Q4	$2.38M	Buy	+13,741	New	+$1.88M	0.01%	226
2019 Q2	–	Sell	-13,741	Closed	-$662K	–	309
2019 Q1	$662K	Hold	13,741	–	–	0.01%	284
2018 Q4	$460K	Hold	13,741	–	–	﹤0.01%	309
2018 Q3	$720K	Hold	13,741	–	–	﹤0.01%	294
2018 Q2	$430K	Hold	13,741	–	–	﹤0.01%	327
2018 Q1	$300K	Hold	13,741	–	–	﹤0.01%	353
2017 Q4	$278K	Hold	13,741	–	–	﹤0.01%	375
2017 Q3	$273K	Hold	13,741	–	–	﹤0.01%	369
2017 Q2	$238K	Buy	+13,741	New	+$177K	﹤0.01%	361

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

TIAA FSB's NVCR Position: Q1 2023 in Review

TIAA FSB sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 2,935 shares — an estimated $215K sold.

TIAA FSB first reported a position in NVCR in Q2 2017 and held it in 14 quarters. The position peaked at $3.05M in Q2 2021. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

TIAA FSB reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
TIAA FSB sold 2,935 NovoCure shares in Q1 2023, an estimated $215K.
TIAA FSB first reported a position in NovoCure in Q2 2017 and held it in 14 quarters.
TIAA FSB's NovoCure position peaked at $3.05M in Q2 2021.
295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on TIAA FSB's 13F filing for Q1 2023, filed 19 Apr 2023.